多瑞醫藥(301075.SZ):子公司1560萬元購得“益肺濟生顆粒”新藥臨牀批件
格隆匯2月22日丨多瑞醫藥(301075.SZ)公佈,近日,公司控股子公司武漢市瑞蒂蓮醫藥科技有限公司(簡稱“瑞蒂蓮醫藥”)與河南中醫藥大學簽署了《技術轉讓合同》,合同約定河南中醫藥大學將“益肺濟生顆粒”臨牀試驗批准通知書及其涵蓋的新藥項目相關的所有專利及非專利技術轉讓給瑞蒂蓮醫藥。“益肺濟生顆粒”項目技術轉讓費及技術服務費和指導費總額為1560萬元。
該協議約定技術轉讓後,瑞蒂蓮醫藥獨家擁有“益肺濟生顆粒”項目的全部技術獨有權,即瑞蒂蓮醫藥擁有“益肺濟生顆粒”新藥證書持有者的署名權,且為該新藥證書的唯一持有人、該藥品的唯一上市許可人,並擁有益肺濟生顆粒獨家生產經營權和項目的完全處理權。
益肺濟生顆粒來源於臨牀經驗方並作為院內製劑應用多年。產品以補肺益腎、止咳平喘功效為主,兼活血通絡;主治慢性阻塞性肺疾病(簡稱“慢阻肺”)穩定期的肺腎氣虛證患者。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.